In particular, according to the Italian consensus on VLCKD, it is absolutely contraindicated in some patients, as patients with organ failure (respiratory failure, kidney failure and moderate-to-severe chronic kidney disease, hepatic failure), some cardiovascular diseases (heart failure, unstable angina, cardiac arrhythmias and recent stroke or myocardial infarction), severe infections, type 1 diabetes mellitus, beta-cell failure in type 2 diabetes mellitus and therapy with sodium/glucose cotransporter-2 inhibitors. Here, SLC5A2 is linked to diabetes mellitus.